Insider Sell: EVP & GENERAL COUNSEL Paul Mahon Sells 6,000 Shares of United Therapeutics ... [Yahoo! Finance]
United Therapeutics Corporation (UTHR)
Last united therapeutics corporation earnings: 4/29 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.unither.com/investor-relations
Company Research
Source: Yahoo! Finance
The transaction was executed at an average price of $237.38 per share, resulting in a total sale amount of $1,424,280. United Therapeutics Corp is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. The company's primary focus is on the development of therapies for pulmonary arterial hypertension (PAH) and other orphan diseases. Warning! GuruFocus has detected 2 Warning Sign with UTHR. Over the past year, the insider has sold a total of 140,500 shares of United Therapeutics Corp and has not made any purchases of the stock. The recent sale by Paul Mahon is part of a trend observed over the past year, where there have been no insider buys but a total of 50 insider sells for the company. Shares of United Therapeutics Corp were trading at $237.38 on the day of the insider's recent sale, giving the company a market capitalization of $11.29 billion. Th
Show less
Read more
Impact Snapshot
Event Time:
UTHR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
UTHR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
UTHR alerts
High impacting United Therapeutics Corporation news events
Weekly update
A roundup of the hottest topics
UTHR
News
- United Therapeutics Co. (NASDAQ: UTHR) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $218.00 to $240.00. They now have a "neutral" rating on the stock.MarketBeat
- United Therapeutics (UTHR) Q1 Earnings Top, Tyvaso Drives Sales [Yahoo! Finance]Yahoo! Finance
- United Therapeutics Corporation (NASDAQ:UTHR) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- United Therapeutics Co. (NASDAQ: UTHR) had its price target raised by analysts at Oppenheimer Holdings Inc. from $375.00 to $400.00. They now have an "outperform" rating on the stock.MarketBeat
- United Therapeutics Co. (NASDAQ: UTHR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $300.00 price target on the stock.MarketBeat
UTHR
Earnings
- 5/1/24 - Beat
UTHR
Sec Filings
- 5/3/24 - Form 4
- 5/3/24 - Form 144
- 5/3/24 - Form 144
- UTHR's page on the SEC website